转自：草原云 然而工作里的难忘瞬间，从来都不是惊天动地的壮举，而是医患之间双向奔赴的温暖。 收到患者给的"压岁钱"。 除夕夜里查房时，一位长期住院的老先生，悄悄从枕头下摸出一个红包塞到她手里，拉着她的手 说："姑娘，过年好，辛苦你了，这是我的一点心意，你别不收，就当是压岁钱。" 虽然她婉拒了红包，却收下了这份沉甸甸的祝福。 这个春节，当团圆的笑语萦绕万家，医院里总有一群身影，始终坚守在岗位上，以责任为灯，以专业为 盾，守护着患者的生命健康，他们用坚守诠释医者初心，用温情搭建医患桥梁，让这个春节多了一份别 样的温暖。 她陪着老先生多聊了许久，听他说说家常，讲讲新年的期盼。还有的患者家属，悄悄在医生办公室里留 下了热腾腾的饺子，并附着一张小纸条"你们守岁，我们守你们"。 内蒙古医科大学附属医院血液内科主治医师骈晓琴的这个春节依旧在岗位上度过，这是她在医院里度过 的第八个春节，除夕、初五的夜班，是她与病房的"新春约定"。 看着那一碗饱满圆润的饺子，骈晓琴心中满是感动——这份彼此牵挂的温暖，让她感到所有疲惫都烟消 云散了。 过年期间的值班，总面临着与日常工作不同的挑战，急诊量激增、危重症患者增多、人力调配压力陡 增， ...

December 31, 2025, 14.1 million shares were repurchased for a total investment amount of EUR 586 million. The second tranche of around EUR 414 million started on January 12, 2026, and is planned to end by May 8, 2026. The entire program is therefore expected to be completed in less than one year instead of within two years.In parallel, net financial debt was further reduced by 6% to EUR 9.2 billion. The corresponding net leverage ratio (net debt/EBITDA) decreased to 2.5x at the end of 2025, compared to 2.9x ...

四、高等级科技奖励获重大突破。全年共获各级科技奖励22项，首次荣获山东省科技进步奖一等奖。 五、科研平台建设水平持续提升。成功牵头获批山东省校企协同创新中心、工程研究中心，以及滨州市 重点实验室、工程研究中心等多个创新平台。 六、科技成果转化平台稳步搭建。联合40余家单位成立黄河三角洲转化医学中心，有力推动科技成果落 地转化。 七、科技发展谋划迈上新台阶。第五届教育科技工作会议成功召开，进一步凝聚临床与科研合力，促进 医学技术创新与交叉融合，为高质量研究转化注入新动能。 齐鲁晚报.齐鲁壹点陈甜田通讯员李晨 一、高水平课题立项再创新高。2025年获国家自然科学基金项目6项、山东省自然科学基金项目20项， 立项数与经费总额均达历史峰值。 二、横向课题立项实现跨越增长。全年立项横向课题83项，其中大额到账经费项目1项，取得历史性突 破。 三、高水平论文发表成果显著。2025年发表SCI论文99篇，其中中科院一区期刊论文10篇，首次在《新 英格兰医学杂志》发表研究论文。 八、有组织科研扎实开展。遵循交叉互补融合原则，以联合攻关模式遴选组建"十大重点科研团队"，系 统开展有组织科研。 九、基础-临床融合成效凸显。推动1 ...

Jefferies adjusted its price target for NASDAQ:WGS to $150, indicating a potential upside of 72.26%.GeneDx reported quarterly earnings of $0.14 per share, surpassing the Zacks Consensus Estimate by 27.27%.The company's revenues for Q4 2025 were $121 million, a significant increase from the previous year and above consensus estimates.GeneDx Holdings Corp. (NASDAQ:WGS) is a company based in Gaithersburg, Maryland, operating within the Zacks Medical Services industry. It focuses on providing genetic testing se ...

CFO Kasandra Rossi said consolidated revenue declined year over year, driven by $26 million of net non-same-unit activity tied to portfolio restructuring, partly offset by acquisition-related and organic growth. On a same-unit basis, the company posted 4% growth , with same-unit pricing up just under 7% and overall patient service volumes down just under 3% .Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?CEO Mark Ordan said adjusted EBITDA was $66 million in the fourth quarter, “in line ...

Core Insights - Pediatrix Medical Group has announced the 47th Annual NEO: The Conference for Neonatology, highlighting its commitment to advancing neonatal care and education [1] Company Overview - Pediatrix Medical Group is focused on providing specialized medical services for neonatology, emphasizing the importance of ongoing education and professional development in the field [1] Industry Context - The conference serves as a significant platform for healthcare professionals in neonatology to share knowledge, discuss advancements, and collaborate on best practices, reflecting the industry's dedication to improving neonatal outcomes [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations during the class period [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of critical information regarding stock price manipulation [5].

Core Insights - Select Medical Holdings Corporation (SEM) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 16 cents, missing the Zacks Consensus Estimate by 31.6%, and reflecting an 11.1% decline year over year [1][9] - Net operating revenues increased by 6.4% year over year to $1.4 billion, surpassing the consensus mark by 2.6% [1][9] Financial Performance - Total costs and expenses rose by 3.2% year over year to $1.3 billion, exceeding estimates by 3.9% [3] - Adjusted EBITDA decreased by 9.8% year over year to $104.7 million, falling short of the estimate of $126.7 million [3] Segment Performance - **Critical Illness Recovery Hospital**: Revenues reached $629.7 million, a 4.9% year-over-year increase, surpassing estimates. Admissions increased by 3% year over year, while patient days declined by 1% [4] - **Rehabilitation Hospital**: Revenues grew by 15.2% year over year to $339.2 million, driven by a 9.6% increase in admissions. Adjusted EBITDA improved by 11.1% year over year to $69.2 million [6][7] - **Outpatient Rehabilitation**: Revenues totaled $324.6 million, a 1.6% year-over-year increase, supported by a 4.9% rise in visits. However, revenue per visit decreased by 3.9% [8][10] Financial Position - As of December 31, 2025, cash and cash equivalents were $26.5 million, down 55.6% from the previous year. Total assets increased by 4.3% to $5.9 billion, while long-term debt rose by 6.6% to $1.8 billion [11] - Net cash from operations was $64.3 million, a decline of 48.7% year over year [12] Shareholder Returns - In 2025, Select Medical repurchased shares worth approximately $96.5 million. A cash dividend of 6.25 cents per share was approved for payment on March 12, 2026 [13] 2026 Outlook - Management projects revenues between $5.6 billion and $5.8 billion for 2026, indicating a 3.6% increase from 2025. Adjusted EBITDA is expected to range from $520 million to $540 million, with EPS anticipated between $1.22 and $1.32 [14]

Core Insights - The strong performance in 2025 was attributed to high patient acuity, a favorable payer mix, and effective financial controls across the portfolio [1] Financial Performance - Same-unit pricing growth was just under 7%, driven by improved revenue cycle management (RCM) cash collections and increased contract administrative fees [1] - Volume declines of approximately 3% in the fourth quarter were due to challenging year-over-year comparisons rather than a fundamental shift in demand [1] Operational Strategies - Management introduced two new physician alignment programs, including stock-price tracking grants, aimed at enhancing clinician retention and operational accountability [1] - Portfolio restructuring activities successfully reduced practice-level salary and benefit expenses, which helped offset same-unit inflationary pressures [1] Market Positioning - The company is leveraging its dominant position in level three and level four NICUs to capture higher-acuity cases that require specialized clinical capabilities [1] - Strategic investments in leadership and clinical quality are prioritized to maintain the company's competitive advantage in neonatology and obstetrics [1]

Financial Data and Key Metrics Changes - The adjusted EBITDA for Q4 2025 was $66 million, aligning with the upwardly adjusted guidance, while the full-year adjusted EBITDA reached $276 million [5][6] - The consolidated revenue decreased due to net non-same-unit activity of $26 million, but same-unit growth was 4% with pricing up just under 7% [7][8] - Operating cash flow for Q4 was $115 million, down from $135 million in the prior year, primarily due to decreases in cash flow from accounts payable and accrued liabilities [9] Business Line Data and Key Metrics Changes - Patient service volumes decreased by just under 3%, with NICU days down about 2% [7][8] - Despite volume declines across service lines, pricing was driven by solid revenue cycle management cash collections and favorable payer mix [7][8] Market Data and Key Metrics Changes - The company anticipates full-year revenue for 2026 to be approximately $1.9 billion, in line with 2025 [10] - The G&A expense for 2026 is projected to be between $230 million and $240 million, compared to $241 million in 2025 [10] Company Strategy and Development Direction - The company is focusing on quality care and has introduced new programs to align physicians with the organization, including cash bonuses and stock price tracking elements [12][13] - There are plans to leverage telemedicine and expand in NICUs and maternal-fetal medicine, with a strong presence in OB hospital medicine [14][15] Management's Comments on Operating Environment and Future Outlook - Management expects steady metrics for 2026, including volume, acuity, and payer mix, with a preliminary outlook of adjusted EBITDA between $280 million and $300 million [6][10] - The company is monitoring potential impacts from ACA subsidies and government enrollment changes, but currently sees no significant changes in payer mix [29][30] Other Important Information - The company ended Q4 with cash of $375 million and net debt of just over $220 million, reflecting a net leverage of just under 1x [9] - The company has not factored any contributions from M&A activity into the 2026 guidance but is open to opportunities that align with its core strengths [11][41] Q&A Session Summary Question: Drivers of revenue growth for 2026 - Management indicated that the revenue growth assumes flat volume and pricing, with no significant changes expected [18] Question: Reasons for negative patient volume year-over-year - The decrease in volume was attributed to tough comparisons from the previous year's fourth quarter [20] Question: Details on variable compensation expenses - Management noted that various factors influenced fourth-quarter operations, emphasizing alignment with physicians rather than smoothing effects [26] Question: Insights on pricing strength and sustainability - Pricing was up just under 7%, driven by strong RCM collections and favorable payer mix, with expectations for stability moving into 2026 [47][50]